Literature DB >> 19451021

Genetic microheterogeneity of emerging H275Y influenza virus A (H1N1) in Toronto, Ontario, Canada from the 2007-2008 respiratory season.

A Eshaghi1, S Bolotin, L Burton, D E Low, T Mazzulli, S J Drews.   

Abstract

BACKGROUND: The H275Y mutation (H274Y in N2 numbering) in the neuraminidase (NA) gene (segment 6) of the influenza virus A (H1N1) genome is linked to oseltamivir resistance.
OBJECTIVES: To determine the percentage of influenza virus A (H1N1) isolates that carry the H275Y mutation in the NA gene in Toronto, Ontario, Canada and to characterize select oseltamivir resistant and susceptible isolates using sequence analysis. STUDY
DESIGN: Sanger sequencing was used to determine strain type and H275Y mutations based on partial sequencing of the hemagglutinin (HA) (segment 4) and NA genes. Mutations in the NS1 gene (segment 8) were determined by Sanger sequencing and pyrosequencing. Statistical analysis of demographics and proportions of H275 and H275Y isolates with mutations was carried out using chi(2) analyses.
RESULTS: The HA gene of influenza virus A (H1N1) isolates collected during the 2007-2008 respiratory season was most like influenza A/Brisbane/59/2007, Clade 2, subclade B. Seventeen percent of these isolates possessed the H275Y NA mutation associated with oseltamivir resistance. H275Y isolates were more likely than H275 isolates to have the mutations A209T and R224G in NS1 (chi(2)=284.9, df=2, p<0.0001).
CONCLUSIONS: During the 2007-2008 influenza season in Toronto, Ontario, Canada, 17% of influenza virus A (H1N1) isolates carried the H275Y mutation associated with oseltamivir resistance. These H275Y isolates were more likely than H275 isolates to exhibit unique microheterogeneity in the gene encoding the NS1 protein.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19451021     DOI: 10.1016/j.jcv.2009.04.010

Source DB:  PubMed          Journal:  J Clin Virol        ISSN: 1386-6532            Impact factor:   3.168


  6 in total

1.  2009 pandemic influenza A (H1N1) virus infection in pediatric oncology and hematopoietic stem cell transplantation patients.

Authors:  Carrye Cost; Evangeline Brock; Beverley Adams-Huet; Jane D Siegel; Monica I Ardura
Journal:  Pediatr Blood Cancer       Date:  2011-01       Impact factor: 3.167

2.  A two-year survey of the oseltamivir-resistant influenza A(H1N1) virus in Yamagata, Japan and the clinical effectiveness of oseltamivir and zanamivir.

Authors:  Yoko Matsuzaki; Katsumi Mizuta; Yoko Aoki; Asuka Suto; Chieko Abiko; Kanako Sanjoh; Kanetsu Sugawara; Emi Takashita; Tsutomu Itagaki; Yuriko Katsushima; Makoto Ujike; Masatsugu Obuchi; Takato Odagiri; Masato Tashiro
Journal:  Virol J       Date:  2010-03-05       Impact factor: 4.099

Review 3.  Deep sequencing: becoming a critical tool in clinical virology.

Authors:  Miguel E Quiñones-Mateu; Santiago Avila; Gustavo Reyes-Teran; Miguel A Martinez
Journal:  J Clin Virol       Date:  2014-06-24       Impact factor: 3.168

4.  Resistance mutation R292K is induced in influenza A(H6N2) virus by exposure of infected mallards to low levels of oseltamivir.

Authors:  Anna Gillman; Shaman Muradrasoli; Hanna Söderström; Johan Nordh; Caroline Bröjer; Richard H Lindberg; Neus Latorre-Margalef; Jonas Waldenström; Björn Olsen; Josef D Järhult
Journal:  PLoS One       Date:  2013-08-12       Impact factor: 3.240

5.  Epistatic interactions between neuraminidase mutations facilitated the emergence of the oseltamivir-resistant H1N1 influenza viruses.

Authors:  Susu Duan; Elena A Govorkova; Justin Bahl; Hassan Zaraket; Tatiana Baranovich; Patrick Seiler; Kristi Prevost; Robert G Webster; Richard J Webby
Journal:  Nat Commun       Date:  2014-10-09       Impact factor: 14.919

6.  Molecular findings from influenza A(H1N1)pdm09 detected in patients from a Brazilian equatorial region during the pandemic period.

Authors:  Maria José Couto Oliveira; Fernando do Couto Motta; Marilda M Siqueira; Paola Cristina Resende; Priscilla da Silva Born; Thiago Moreno L Souza; Milene Mesquita; Maria de Lourdes Aguiar Oliveira; Sharon Carney; Wyller Alencar de Mello; Vera Magalhães
Journal:  Mem Inst Oswaldo Cruz       Date:  2014-10-14       Impact factor: 2.743

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.